PBMs Sue To Block FTC's In-House Insulin Pricing Case
By Matthew Perlman · November 20, 2024, 4:59 PM EST
Caremark Rx, Express Scripts and OptumRx have lodged a constitutional challenge of the Federal Trade Commission's in-house case accusing the pharmacy benefits managers of artificially inflating insulin prices through unfair rebate...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login